Marina Picillo1, Raffaele Palladino2, Marcello Moccia3, Roberto Erro4, Marianna Amboni5, Carmine Vitale6, Paolo Barone1, Maria Teresa Pellecchia7. 1. Center for Neurodegenerative Diseases (CEMAND), Department of Medicine and Surgery, Neuroscience Section, University of Salerno, Italy. 2. Department of Primary Care and Public Health, Imperial College, London, United Kingdom; Department of Public Health, Federico II University, Naples, Italy. 3. Department of Neurosciences, Reproductive Sciences and Odontostomatology, Federico II University, Naples, Italy. 4. Department of Neurological and Movement Sciences, University of Verona, Policlinico Borgo Roma, Verona, Italy. 5. IDC Hermitage-Capodimonte, Naples, Italy. 6. IDC Hermitage-Capodimonte, Naples, Italy; University Parthenope, Naples, Italy. 7. Center for Neurodegenerative Diseases (CEMAND), Department of Medicine and Surgery, Neuroscience Section, University of Salerno, Italy. Electronic address: mpellecchia@unisa.it.
Abstract
INTRODUCTION: In Parkinson's disease (PD), non motor symptoms can fluctuate either along or irrespective to motor on/off phenomena. Prospective studies suggest that higher motor scores and levodopa dosage, younger age at onset and female gender represent risk factors for motor fluctuations' development. Yet, the predictors of development of non motor fluctuations (NMF) are less clear. In this prospective study, we aimed to assess the relationship between NMF and gender along with other potential risk factors. METHODS: Forty-seven (16 women/31 men) de novo, drug-naïve PD patients have been followed for 4 years since diagnosis. Motor and non motor fluctuations were evaluated with the 19-item Wearing off Questionnaire (WOQ-19). The association between gender and NMF was explored with multivariable regression models adjusted for age at onset, motor and non motor symptoms at diagnosis and levodopa intake at follow up. RESULTS: Female gender was more likely associated with a diagnosis of NMF (adjusted odds ratio, AOR = 5.33,95%CI = 1.21-23.4, p = 0.027), but not with a diagnosis of generic wearing off at follow up (OR = 3.66, 95%CI = 0.8-16.8, p = 0.097). Women had greater likelihood of developing higher WOQ-19 Non motor scores (AOR = 4.58, 95%CI = 1.23-17.03, p = 0.023), but not higher WOQ-19 Total scores (AOR = 2.88, 95%CI = 0.86-9.71, p = 0.087) compared to men. Notwithstanding, no gender differences were detected in medication intake. CONCLUSIONS: We showed that female gender represents a major risk factor for the development of NMF. There were no gender differences in medication intake, thus NMF in women remain mostly underestimated and not properly treated. From a practical standpoint, clinicians should take into account the role of gender in the management of NMF in PD.
INTRODUCTION: In Parkinson's disease (PD), non motor symptoms can fluctuate either along or irrespective to motor on/off phenomena. Prospective studies suggest that higher motor scores and levodopa dosage, younger age at onset and female gender represent risk factors for motor fluctuations' development. Yet, the predictors of development of non motor fluctuations (NMF) are less clear. In this prospective study, we aimed to assess the relationship between NMF and gender along with other potential risk factors. METHODS: Forty-seven (16 women/31 men) de novo, drug-naïve PDpatients have been followed for 4 years since diagnosis. Motor and non motor fluctuations were evaluated with the 19-item Wearing off Questionnaire (WOQ-19). The association between gender and NMF was explored with multivariable regression models adjusted for age at onset, motor and non motor symptoms at diagnosis and levodopa intake at follow up. RESULTS: Female gender was more likely associated with a diagnosis of NMF (adjusted odds ratio, AOR = 5.33,95%CI = 1.21-23.4, p = 0.027), but not with a diagnosis of generic wearing off at follow up (OR = 3.66, 95%CI = 0.8-16.8, p = 0.097). Women had greater likelihood of developing higher WOQ-19 Non motor scores (AOR = 4.58, 95%CI = 1.23-17.03, p = 0.023), but not higher WOQ-19 Total scores (AOR = 2.88, 95%CI = 0.86-9.71, p = 0.087) compared to men. Notwithstanding, no gender differences were detected in medication intake. CONCLUSIONS: We showed that female gender represents a major risk factor for the development of NMF. There were no gender differences in medication intake, thus NMF in women remain mostly underestimated and not properly treated. From a practical standpoint, clinicians should take into account the role of gender in the management of NMF in PD.
Authors: Joseph Classen; Jiri Koschel; Christian Oehlwein; Klaus Seppi; Peter Urban; Christian Winkler; Ullrich Wüllner; Alexander Storch Journal: J Neural Transm (Vienna) Date: 2017-07-12 Impact factor: 3.575
Authors: Carmen Rodriguez-Blazquez; Anette Schrag; Alexandra Rizos; K Ray Chaudhuri; Pablo Martinez-Martin; Daniel Weintraub Journal: Mov Disord Clin Pract Date: 2020-12-21
Authors: Srishti Shrestha; Freya Kamel; David M Umbach; Laura E Beane Freeman; Stella Koutros; Michael Alavanja; Dale P Sandler; Honglei Chen Journal: PLoS One Date: 2017-09-27 Impact factor: 3.240
Authors: Pietro Crispino; Miriam Gino; Elena Barbagelata; Tiziana Ciarambino; Cecilia Politi; Immacolata Ambrosino; Rosalia Ragusa; Marina Marranzano; Antonio Biondi; Marco Vacante Journal: Int J Environ Res Public Health Date: 2020-12-29 Impact factor: 3.390
Authors: Tanya Simuni; Chelsea Caspell-Garcia; Christopher S Coffey; Daniel Weintraub; Brit Mollenhauer; Shirley Lasch; Caroline M Tanner; Danna Jennings; Karl Kieburtz; Lana M Chahine; Kenneth Marek Journal: J Neurol Neurosurg Psychiatry Date: 2017-10-06 Impact factor: 10.154